{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:35:39Z","timestamp":1762544139561,"version":"3.43.0"},"reference-count":72,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti\u2013cytotoxic T-lymphocyte\u2013associated protein 4) + nivolumab (anti\u2013PD-1) in untreated, metastatic melanoma has achieved a ten-year melanoma-specific survival of 52%. However, approximately 40%-55% of patients with metastatic melanoma have primary resistance and do not initially respond to anti\u2013PD-1, and an additional 25% of patients develop secondary resistance, exhibiting an initial response followed by disease progression. In PD-1\u2013refractory melanoma, treatment options are limited. Addition of ipilimumab, relatlimab (anti-LAG3), or lenvatinib (VEGFR TKI) has minimal to modest efficacy. Switching to targeted BRAF\/MEK inhibition improves survival for BRAF-mutant disease. MEK and KIT inhibitors have limited activity in NRAS- and KIT-mutant metastatic melanoma, respectively. Recently, personalized, autologous tumor-infiltrating lymphocyte therapy has become a US Food and Drug Administration\u2013approved second-line option; lifileucel demonstrates durable response (approximately 30%) in heavily pretreated, metastatic melanoma. Emerging therapeutics that show promising clinical benefit in ongoing clinical trials include novel engineered oncolytic viral and human leukocyte antigen (HLA)\u2013restricted immune-mediated T-cell therapies. As a therapy which is limited to patients who are HLA-A*02:01, T-cell receptor (TCR) engineered T cells (TCR-T) iterates on personalized adoptive cell transfer, and immune mobilizing monoclonal TCRs against cancer are CD3 bispecifics that bind glycoprotein 100 (tebentafusp, approved for metastatic uveal melanoma) or PRAME to activate T cells. Finally, in patients at high risk for immune-related adverse events (irAEs), ICI should still be considered. ICI may be given with modified immunosuppression in patients with autoimmune disease or previous organ transplantation. Cumulative data support safe administration in older patients and in ICI rechallenge for patients with previous irAE.<\/jats:p>","DOI":"10.1200\/edbk-25-473856","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:59:07Z","timestamp":1744732747000},"source":"Crossref","is-referenced-by-count":2,"title":["Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open"],"prefix":"10.1200","volume":"45","author":[{"given":"Urvashi Mitbander","family":"Joshi","sequence":"first","affiliation":[{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Hundal","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonaphine R.","family":"Mata","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan D.","family":"Schollenberger","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University, Baltimore, MD"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Govind","family":"Warrier","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University, Baltimore, MD"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Lipson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University, Baltimore, MD"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Funchain","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36979-y"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01998"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00735-6"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02072"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114120"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.471"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02322"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.010"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7836"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100520"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30180-8"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00221"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.158"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8511"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0682-1"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9517"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2287"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02355"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22891"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006747"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9594"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9507"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9602"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.074"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"e_1_3_4_43_2","first-page":"100589","article-title":"Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study","volume":"20","author":"Wermke M","year":"2023","unstructured":"Wermke M, Chesney JA, Whitman E, et al: Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Ann Oncol 20:100589, 2023 (suppl 1)","journal-title":"Ann Oncol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9515"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00809-z"},{"key":"e_1_3_4_46_2","article-title":"687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients","volume":"12","author":"Wermke M","year":"2024","unstructured":"Wermke M, Alsdorf W, Araujo DM, et al: 687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients. J Immunother Cancer 12, 2024 (suppl 2)","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30642"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0305"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3158"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111797"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002567"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0309-7"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.972"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9553"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9538"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg260"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0195"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01498"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0362-5"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168468"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112826"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00404-2"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-0173-8"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100282"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1750-0"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0450"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T19:59:11Z","timestamp":1754683151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473856"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473856","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"type":"print","value":"1548-8748"},{"type":"electronic","value":"1548-8756"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473856"}}